Short Interest in iSpecimen Inc. (NASDAQ:ISPC) Drops By 72.6%

iSpecimen Inc. (NASDAQ:ISPC) was the recipient of a large decrease in short interest during the month of January. As of January 15th, there was short interest totaling 311,313 shares, a decrease of 72.6% from the December 31st total of 1,136,955 shares. Currently, 3.6% of the shares of the company are sold short. Based on an average daily trading volume, of 1,172,021 shares, the days-to-cover ratio is currently 0.3 days. Based on an average daily trading volume, of 1,172,021 shares, the days-to-cover ratio is currently 0.3 days. Currently, 3.6% of the shares of the company are sold short.

iSpecimen Stock Up 6.2%

ISPC stock traded up $0.02 during trading on Wednesday, reaching $0.36. 87,412 shares of the company’s stock were exchanged, compared to its average volume of 913,934. The firm has a market cap of $3.50 million, a PE ratio of -0.05 and a beta of 1.83. iSpecimen has a 1-year low of $0.26 and a 1-year high of $3.18. The company’s fifty day moving average price is $0.39 and its 200-day moving average price is $0.81.

iSpecimen (NASDAQ:ISPC) last issued its quarterly earnings data on Monday, November 17th. The company reported ($0.48) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.80) by $3.32. The business had revenue of $0.11 million for the quarter, compared to analysts’ expectations of $3.33 million. iSpecimen had a negative net margin of 343.86% and a negative return on equity of 531.78%.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in iSpecimen stock. Virtu Financial LLC bought a new position in iSpecimen Inc. (NASDAQ:ISPC) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 63,257 shares of the company’s stock, valued at approximately $82,000. Virtu Financial LLC owned 0.65% of iSpecimen at the end of the most recent reporting period. 13.62% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of iSpecimen in a research note on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, iSpecimen currently has a consensus rating of “Sell”.

iSpecimen Company Profile

iSpecimen, Inc (NASDAQ:ISPC) operates an online life sciences marketplace designed to connect researchers with human biological specimens and associated clinical data. The company’s platform streamlines the sourcing of biospecimens—such as plasma, serum, fresh and frozen tissue, saliva, urine and peripheral blood mononuclear cells (PBMCs)—by matching demand from pharmaceutical, biotechnology, diagnostic and academic organizations with supply from a wide network of clinical sites and biobanks.

Through its on-demand procurement model, iSpecimen provides customized specimen collection and fulfillment services that help accelerate research timelines and improve data quality.